Balazs Halmos, MD is a professor of Medical Oncology in the Department of Oncology, a professor of Oncology and Hematology in the Department of Medicine, and the chief of Thoracic Oncology at Albert Einstein College of Medicine, Montefiore Medical Center. Martin F. Dietrich, MD, PhD is a medical oncologist at Florida Cancer Specialists & Research Institute.

Roy S. Herbst, MD, PhD, is an ensign professor of medicine in Medical Oncology and professor of Pharmacology, the director of the Center for Thoracic Cancers, and the deputy director of clinical affairs and assistant dean for Translational Research at Yale School of Medicine, and the chief of Medical Oncology and associate cancer center director of Translational Science at Yale Cancer Center, Smilow Cancer Hospital. Suresh S. Ramalingam, MD, FACP, FASCO, is the director of the Lung Cancer Program at Winship Cancer Institute of Emory University, and a professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, and director in the Division of Medical Oncology, Department of Hematology and Medical Oncology at Emory University School of Medicine.

Mark Socinski, MD, is a medical oncologist and executive director of the Thoracic Center at AdventHealth Cancer Institute. Heather Wakelee, MD, FASCO, is professor of medicine and chief of the Division of Oncology at Stanford University School of Medicine, the interim medical director of Stanford Cancer Center, deputy director of Stanford Cancer Institute, and president of the International Association for the Study of Lung Cancer.

Halmos, Dietrich, Ramalingam, Socinski and Wakelee explain that CEACAM5-targeted therapy shows great promise as a novel therapeutic alternative in NSCLC. However, CEACAM5-targeted therapy must prove more effective than its current second-line competitors to justify its use. 

Moreover, the long-term management of treatment-related ocular adverse effects may lead to the partnership of community ophthalmologists. Despite the potential benefits of collaborating with ophthalmologists, this may lead to the complication of the treatment process. Ultimately, additional efficacy and safety data are needed to support the widespread adoption of CEACAM5-targeted therapy in clinical practice. 

Videos

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer. 

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

Data from the following clinical trials are discussed:

P15.01 - AMG 757, a Half-life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer

OA11.04 - Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I/II Trial

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.  

WCLC Updates in Small Cell Lung Cancer 

Data from the following clinical trial are discussed: 

 OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced Stage III NSCLC: KEYNOTE-799

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC). 

WCLC Updates in Locally Advanced NSCLC  

 PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC). 

WCLC Updates in Neoadjuvant Therapy for NSCLC 

OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in 

PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

WCLC Updates in Immunotherapy for NSCLC

OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

OA03.04 - Efficacy and Safety of the Novel HER3-Directed Antibody-Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in 

OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC). 

WCLC Updates on the Emergence of ADCs in NSCLC

PS0 1.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in 

 p.G12C Mutated Non–Small Cell Lung Cancer

OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

 Exon 20 Insertion Mutant Non–Small Cell Lung Cancer

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).

Heather A. Wakelee, MD, Stanford University Medical Center

Articles